NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 866.2 DKK | +0.41% |
|
-0.36% | +24.08% |
| Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
| Apr. 15 | More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm | RE |
Presenter SpeechHelge Lund (Executives)Good afternoon. On behalf of the Board, a warm welcome ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
866.2
DKK
Average target price
904.2
DKK
Spread / Average Target
+4.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.08% | 550B | |
| +24.60% | 672B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B | |
| -3.20% | 113B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S - Shareholder/Analyst Call
